Licence to save: a UK survey of anti-VEGF use for the eye in 2015

Eye (Lond). 2016 Nov;30(11):1404-1406. doi: 10.1038/eye.2016.154. Epub 2016 Aug 12.

Authors

A K Shalaby¹, K Lewis¹, K Bush¹, P R Meredith^{1

2}, S Di Simplicio¹, A J Lockwood^{1

2

3}

Affiliations

¹ Department of Ophthalmology, University Hospital Southampton, Southampton, UK.
² Department of Ophthalmology, Queen Alexandra Hospital, Portsmouth, UK.
³ Moorfields Eye Hospital, London, UK.

No abstract available

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / economics*
Bevacizumab / administration & dosage
Bevacizumab / economics
Cost Savings / economics
Drug Costs / legislation & jurisprudence*
Drug Prescriptions / economics
Drug Utilization / economics*
Health Surveys
Humans
Legislation, Drug / economics*
Macular Degeneration / drug therapy
Macular Degeneration / economics
Macular Edema / drug therapy
Macular Edema / economics
Off-Label Use / economics
Ranibizumab / administration & dosage
Ranibizumab / economics
Receptors, Vascular Endothelial Growth Factor / administration & dosage
Recombinant Fusion Proteins / administration & dosage
Recombinant Fusion Proteins / economics
State Medicine / economics
United Kingdom
Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
VEGFA protein, human
Vascular Endothelial Growth Factor A
aflibercept
Bevacizumab
Receptors, Vascular Endothelial Growth Factor
Ranibizumab